→ Peter Griffith will be the second high-profile exec to leave Amgen this year when he retires on Sept. 1. Thomas Dittrich will replace him as CFO and return to Amgen …
FDA delays verdict on AZ breast cancer drug
After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.
